132 related articles for article (PubMed ID: 12485952)
21. Mechanism-based inactivation of human cytochrome P450 2B6 by clopidogrel: involvement of both covalent modification of cysteinyl residue 475 and loss of heme.
Zhang H; Amunugama H; Ney S; Cooper N; Hollenberg PF
Mol Pharmacol; 2011 Nov; 80(5):839-47. PubMed ID: 21862689
[TBL] [Abstract][Full Text] [Related]
22. The licorice root derived isoflavan glabridin inhibits the activities of human cytochrome P450S 3A4, 2B6, and 2C9.
Kent UM; Aviram M; Rosenblat M; Hollenberg PF
Drug Metab Dispos; 2002 Jun; 30(6):709-15. PubMed ID: 12019199
[TBL] [Abstract][Full Text] [Related]
23. Thr302 is the site for the covalent modification of human cytochrome P450 2B6 leading to mechanism-based inactivation by tert-butylphenylacetylene.
Lin HL; Zhang H; Pratt-Hyatt MJ; Hollenberg PF
Drug Metab Dispos; 2011 Dec; 39(12):2431-9. PubMed ID: 21930824
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of bupropion metabolism by selegiline: mechanism-based inactivation of human CYP2B6 and characterization of glutathione and peptide adducts.
Sridar C; Kenaan C; Hollenberg PF
Drug Metab Dispos; 2012 Dec; 40(12):2256-66. PubMed ID: 22936314
[TBL] [Abstract][Full Text] [Related]
25. Selective mechanism-based inactivation of cytochromes P-450 2B1 and P-450 2B6 by a series of xanthates.
Yanev S; Kent UM; Pandova B; Hollenberg PF
Drug Metab Dispos; 1999 May; 27(5):600-4. PubMed ID: 10220489
[TBL] [Abstract][Full Text] [Related]
26. Structures of cytochrome P450 2B6 bound to 4-benzylpyridine and 4-(4-nitrobenzyl)pyridine: insight into inhibitor binding and rearrangement of active site side chains.
Shah MB; Pascual J; Zhang Q; Stout CD; Halpert JR
Mol Pharmacol; 2011 Dec; 80(6):1047-55. PubMed ID: 21875942
[TBL] [Abstract][Full Text] [Related]
27. Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6.
Sridar C; Kent UM; Notley LM; Gillam EM; Hollenberg PF
J Pharmacol Exp Ther; 2002 Jun; 301(3):945-52. PubMed ID: 12023523
[TBL] [Abstract][Full Text] [Related]
28. Metabolism of efavirenz and 8-hydroxyefavirenz by P450 2B6 leads to inactivation by two distinct mechanisms.
Bumpus NN; Kent UM; Hollenberg PF
J Pharmacol Exp Ther; 2006 Jul; 318(1):345-51. PubMed ID: 16611850
[TBL] [Abstract][Full Text] [Related]
29. Identification of 17-alpha-ethynylestradiol-modified active site peptides and glutathione conjugates formed during metabolism and inactivation of P450s 2B1 and 2B6.
Kent UM; Lin HL; Mills DE; Regal KA; Hollenberg PF
Chem Res Toxicol; 2006 Feb; 19(2):279-87. PubMed ID: 16485904
[TBL] [Abstract][Full Text] [Related]
30. The naturally occurring cytochrome P450 (P450) 2B6 K262R mutant of P450 2B6 exhibits alterations in substrate metabolism and inactivation.
Bumpus NN; Sridar C; Kent UM; Hollenberg PF
Drug Metab Dispos; 2005 Jun; 33(6):795-802. PubMed ID: 15769884
[TBL] [Abstract][Full Text] [Related]
31. Investigation of the mechanisms underlying the differential effects of the K262R mutation of P450 2B6 on catalytic activity.
Bumpus NN; Hollenberg PF
Mol Pharmacol; 2008 Oct; 74(4):990-9. PubMed ID: 18621926
[TBL] [Abstract][Full Text] [Related]
32. Mechanism-based inactivation of cytochrome P450 3A4 by 17 alpha-ethynylestradiol: evidence for heme destruction and covalent binding to protein.
Lin HL; Kent UM; Hollenberg PF
J Pharmacol Exp Ther; 2002 Apr; 301(1):160-7. PubMed ID: 11907170
[TBL] [Abstract][Full Text] [Related]
33. Mechanism-based inactivation of cytochrome P450 2B1 by 7-ethynylcoumarin: verification of apo-P450 adduction by electrospray ion trap mass spectrometry.
Regal KA; Schrag ML; Kent UM; Wienkers LC; Hollenberg PF
Chem Res Toxicol; 2000 Apr; 13(4):262-70. PubMed ID: 10775326
[TBL] [Abstract][Full Text] [Related]
34. Crystal structure of a cytochrome P450 2B6 genetic variant in complex with the inhibitor 4-(4-chlorophenyl)imidazole at 2.0-A resolution.
Gay SC; Shah MB; Talakad JC; Maekawa K; Roberts AG; Wilderman PR; Sun L; Yang JY; Huelga SC; Hong WX; Zhang Q; Stout CD; Halpert JR
Mol Pharmacol; 2010 Apr; 77(4):529-38. PubMed ID: 20061448
[TBL] [Abstract][Full Text] [Related]
35. Decreased susceptibility of the cytochrome P450 2B6 variant K262R to inhibition by several clinically important drugs.
Talakad JC; Kumar S; Halpert JR
Drug Metab Dispos; 2009 Mar; 37(3):644-50. PubMed ID: 19074527
[TBL] [Abstract][Full Text] [Related]
36. Inactivation of cytochrome P450 2B1 by benzyl isothiocyanate, a chemopreventative agent from cruciferous vegetables.
Goosen TC; Kent UM; Brand L; Hollenberg PF
Chem Res Toxicol; 2000 Dec; 13(12):1349-59. PubMed ID: 11123978
[TBL] [Abstract][Full Text] [Related]
37. Mechanism-based inactivation of cytochrome P450 2B1 by 2-ethynylnaphthalene: identification of an active-site peptide.
Roberts ES; Hopkins NE; Alworth WL; Hollenberg PF
Chem Res Toxicol; 1993; 6(4):470-9. PubMed ID: 8374044
[TBL] [Abstract][Full Text] [Related]
38. Comparison of in vitro metabolism of ticlopidine by human cytochrome P450 2B6 and rabbit cytochrome P450 2B4.
Talakad JC; Shah MB; Walker GS; Xiang C; Halpert JR; Dalvie D
Drug Metab Dispos; 2011 Mar; 39(3):539-50. PubMed ID: 21156812
[TBL] [Abstract][Full Text] [Related]
39. Measurement of in vitro cytochrome P450 2B6 activity.
Walsky RL; Obach RS
Curr Protoc Toxicol; 2009; Chapter 4():Unit4.27. PubMed ID: 23045012
[TBL] [Abstract][Full Text] [Related]
40. Mechanistic studies of cytochrome P450 2B1 inactivation by xanthates.
Yanev SG; Kent UM; Roberts ES; Ballou DP; Hollenberg PF
Arch Biochem Biophys; 2000 Jun; 378(1):157-66. PubMed ID: 10871056
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
